EverPoint Asset Management’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

EverPoint Asset Management’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-26,500	Closed	-$5.37M	–	568
2015 Q4	$5.37M	Buy	+26,500	New	+$4.74M	0.11%	237
2015 Q3	–	Sell	-16,500	Closed	-$3.51M	–	552
2015 Q2	$3.51M	Buy	16,500 +11,193	+211%	+$2.74M	0.06%	332
2015 Q1	$1.23M	Buy	+5,307	New	+$1.28M	0.02%	456

Other funds holding BLCM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EverPoint Asset Management's BLCM Position: Q1 2016 in Review

EverPoint Asset Management sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q1 2016, closing a stake of 26,500 shares — an estimated $5.37M sold.

EverPoint Asset Management first reported a position in BLCM in Q1 2015 and held it in 3 quarters. The position peaked at $5.37M in Q4 2015. 78 funds tracked by Wall St. Rank hold BLCM as of Q1 2016.

EverPoint Asset Management reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q1 2016 after selling out during the quarter.
EverPoint Asset Management sold 26,500 Bellicum Pharmaceuticals, Inc. shares in Q1 2016, an estimated $5.37M.
EverPoint Asset Management first reported a position in Bellicum Pharmaceuticals, Inc. in Q1 2015 and held it in 3 quarters.
EverPoint Asset Management's Bellicum Pharmaceuticals, Inc. position peaked at $5.37M in Q4 2015.
78 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q1 2016.

Based on EverPoint Asset Management's 13F filing for Q1 2016, filed 16 May 2016.